

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013;63:11–30.
2. Simard EP, Ward EM, Siegel R, et al. Cancers with increasing incidence trends in the United States: 1999 through 2008. *CA Cancer J Clin* 2012;62:118–128.
3. Jemal A, Saraiya M, Patel P, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006. *J Am Acad Dermatol* 2011;65:S17–S25.e1–e3.
4. Hall HI, Miller DR, Rogers JD, et al. Update on the incidence and mortality from melanoma in the United States. *J Am Acad Dermatol* 1999;40:35–42.
5. Ekwueme DU, Guy GP Jr, Li C, et al. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity—United States, 2000 to 2006. *J Am Acad Dermatol* 2011;65:S133–S143.
6. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. *J Clin Oncol* 2009;27:6199–6206.
7. Gilchrist BA, Eller MS, Geller AC, et al. The pathogenesis of melanoma induced by ultraviolet radiation. *N Engl J Med* 1999;340:1341–1348.
8. Kanavy HE, Gerstenblith MR. Ultraviolet radiation and melanoma. *Semin Cutan Med Surg* 2011;30:222–228.
9. Berger MF, Hodis E, Herrerman TP, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. *Nature* 2012;485:502–506.
10. Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. *Hum Mutat* 2007;28:578–588.
11. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. *Cell* 2012;150:251–263.
12. Krauthammer M, Kong Y, Ha BH, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. *Nat Genet* 2012;44:1006–1014.
13. Bauer J, Curtin JA, Pinkel D, et al. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. *J Invest Dermatol* 2007;127:179–182.
14. Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. *Am J Pathol* 2000;157:967–972.
15. Chin L, Pomerantz J, Polsky D, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. *Genes Dev* 1997;11:2822–2834.
16. Ackermann J, Fruttschi M, Kaloulis K, et al. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. *Cancer Res* 2005;65:4005–4011.
17. Eskandarpour M, Kiai S, Zhu C, et al. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. *Int J Cancer* 2005;115:65–73.
18. Kwong LN, Costello JC, Liu H, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. *Nat Med* 2012;18:1503–1510.
19. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. *N Engl J Med* 2005;353:2135–2147.
20. Menzies AM, Haydu LE, Visintin L, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. *Clin Cancer Res* 2012;18:3242–3249.
21. Bucheit AD, Syklawer E, Jakob JA, et al. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. *Cancer* 2013;119:3821–3829.
22. Handolias D, Salemi R, Murray W, et al. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. *Pigment Cell Melanoma Res* 2010;23:210–215.
23. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. *Nat Genet* 2003;33:19–20.
24. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. *Cell* 2004;116:855–867.
25. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. *Nature* 2002;417:949–954.
26. Heidom SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. *Cell* 2010;140:209–221.
27. Goel VK, Lazar AJ, Warneke CL, et al. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. *J Invest Dermatol* 2006;126:154–160.
28. Patton EE, Widlund HR, Kutok JL, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. *Curr Biol* 2005;15:249–254.
29. Dhomen N, Reis-Filho JS, da Rocha Dias S, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. *Cancer Cell* 2009;15:294–303.
30. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAF600-associated senescence-like cell cycle arrest of human naevi. *Nature* 2005;436:720–724.
31. Dankort D, Curley DP, Cartridge RA, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. *Nat Genet* 2009;41:544–552.
32. Hingorani SR, Jacobetz MA, Robertson GP, et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. *Cancer Res* 2003;63:5198–5202.
33. Wellbrock C, Ogilvie L, Hedley D, et al. V599EB-RAF is an oncogene in melanocytes. *Cancer Res* 2004;64:2338–2342.
34. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncol* 2014;15:323–332.
35. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 2012;380:358–365.
36. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. *Nature* 2010;464:431–435.
37. Poulidakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. *Nature* 2010;464:427–430.
38. Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. *J Clin Oncol* 2012;30:316–321.
39. Su F, Viroo A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. *N Engl J Med* 2012;366:207–215.
40. Smalley KS, Xiao M, Villanueva J, et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. *Oncogene* 2009;28:85–94.
41. Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. *Cancer Res* 2008;68:4853–4861.
42. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. *Cancer Cell* 2010;18:683–695.
43. Poulidakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). *Nature* 2011;480:387–390.
44. Nikolaev SI, Rimoldi D, Iseli C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. *Nat Genet* 2011;44:133–139.
45. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. *Nature* 2006;439:358–362.
46. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. *N Engl J Med* 2012;367:107–114.
47. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N Engl J Med* 2012;367:1694–1703.
48. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. *Lancet Oncol* 2013;14:249–256.
49. Kwong LN, Davies MA. Targeted therapy for melanoma: rational combinatorial approaches. *Oncogene* 2014;33:1–9.
50. Maertens O, Johnson B, Hollstein P, et al. Elucidating distinct roles for NF1 in melanomagenesis. *Cancer Discov* 2013;3:338–349.
51. Whittaker SR, Theurillat JP, Van Allen E, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. *Cancer Discov* 2013;3:350–362.
52. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. *Nature* 2010;468:973–977.
53. Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. *Nature* 2012;487:500–504.
54. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. *Nature* 2010;468:968–972.
55. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. *J Clin Oncol* 2011;29:3085–3096.
56. Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. *Cancer Discov* 2014;4:94–109.
57. Wagle N, Van Allen EM, Treacy DJ, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. *Cancer Discov* 2014;4:61–68.
58. Johannessen CM, Johnson LA, Piccioni F, et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. *Nature* 2013;504:138–142.
59. Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. *Cancer Res* 2007;67:2632–2642.
60. Lin WM, Baker AC, Beroukhim R, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. *Cancer Res* 2008;68:664–673.
61. FitzGerald MG, Harkin DP, Silva-Arrieta S, et al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. *Proc Natl Acad Sci U S A* 1996;93:8541–8545.
62. Zuo L, Weger J, Yang Q, et al. Germ-line mutations in the p16INK4a binding domain of CDK4 in familial melanoma. *Nat Genet* 1996;12:97–99.

63. Sharpless NE, Kannan K, Xu J, et al. Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. *Oncogene* 2003;22:5055–5059.
64. Muthusamy V, Hobbs C, Noqueira C, et al. Amplification of CDK4 and MDM2 in malignant melanoma. *Genes Chromosomes Cancer* 2006;45:447–454.
65. Sotillo R, Garcia JF, Ortega S, et al. Invasive melanoma in Cdk4-targeted mice. *Proc Natl Acad Sci U S A* 2001;98:13312–13317.
66. Sauter ER, Yeo UC, von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. *Cancer Res* 2002;62:3200–3206.
67. Smalley KS, Lioni M, Dalla Palma M, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E mutated melanomas. *Mol Cancer Ther* 2008;7:2876–2883.
68. Nathanson KL, Martin AM, Wubbenhorst B, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). *Clin Cancer Res* 2013;19:4868–4878.
69. Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. *J Natl Cancer Inst* 2004;96:357–363.
70. Bardeesy N, Bastian BC, Hezel A, et al. Dual inactivation of RB and p53 pathways in RAS-induced melanomas. *Mol Cell Biol* 2001;21:2144–2153.
71. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. *Oncogene* 2008;27:5497–5510.
72. Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. *Cancer Discov* 2014;4:80–93.
73. Davies MA, Stenke-Hale K, Lin E, et al. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. *Clin Cancer Res* 2009;15:7538–7546.
74. Wu H, Goel W, Haluska FG. PTEN signaling pathways in melanoma. *Oncogene* 2003;22:3113–3122.
75. Nogueira C, Kim KH, Sung H, et al. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. *Oncogene* 2010;29:6222–6232.
76. Robertson GP. Functional and therapeutic significance of Akt deregulation in malignant melanoma. *Cancer Metastasis Rev* 2005;24:273–285.
77. Vasudevan KM, Barbie DA, Davies MA, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. *Cancer Cell* 2009;16:21–32.
78. Kwong LN, Davies MA. Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. *Clin Cancer Res* 2013;19:5310–5319.
79. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. *Nature* 2007;448:439–444.
80. Davies MA, Stenke-Hale K, Tellez C, et al. A novel AKT3 mutation in melanoma tumours and cell lines. *Br J Cancer* 2008;99:1265–1268.
81. Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. *Cancer Res* 2004;64:7002–7010.
82. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. *Science* 2004;304:554.
83. Omholt K, Krockel D, Ringborg U, et al. Mutations of PIK3CA are rare in cutaneous melanoma. *Melanoma Res* 2006;16:197–200.
84. Marsh Durban V, Deuker MM, Bosenberg MW, et al. Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. *J Clin Invest* 2013;123:5104–5118.
85. Nishimura EK, Jordan SA, Oshima H, et al. Dominant role of the niche in melanocyte stem-cell fate determination. *Nature* 2002;416:854–860.
86. Woodman SE, Davies MA. Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics. *Biochem Pharmacol* 2010;80:568–574.
87. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. *J Clin Oncol* 2006;24:4340–4346.
88. Liang R, Wallace AR, Schadendorf D, et al. The phosphatidylinositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma. *Pigment Cell Melanoma Res* 2011;24:714–723.
89. Jiang X, Zhou J, Yuen NK, et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. *Clin Cancer Res* 2008;14:7726–7732.
90. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. *JAMA* 2011;305:2327–2334.
91. Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. *J Clin Oncol* 2013;31:3182–3190.
92. Bastian BC, LeBoit PE, Hamm H, et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. *Cancer Res* 1998;58:2170–2175.
93. Recio JA, Noonan FP, Takayama H, et al. Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis. *Cancer Res* 2002;62:6724–6730.
94. Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. *Nature* 2012;487:505–509.
95. Prickett TD, Agrawal NS, Wei X, et al. Analysis of the tyrosine kinase in melanoma reveals recurrent mutations in ERBB4. *Nat Genet* 2009;41:1127–1132.
96. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature* 2005;436:117–122.
97. Garraway LA, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. *Nat Rev Cancer* 2006;6:593–602.
98. Yokoyama S, Woods SL, Boyle GM, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. *Nature* 2011;480:99–103.
99. Bertolotto C, Lesueur D, Giuliano S, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. *Nature* 2011;480:94–98.
100. Haq R, Shoag J, Andreu-Perez P, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. *Cancer Cell* 2013;23:302–315.
101. Haq R, Yokoyama S, Hawryluk EB, et al. BCL2A1 is a lineage-specific anti-apoptotic melanoma oncogene that confers resistance to BRAF inhibition. *Proc Natl Acad Sci U S A* 2013;110:4321–4326.
102. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. *Genes Dev* 2006;20:2149–2182.
103. Price ER, Ding HF, Badalian T, et al. Lineage-specific signaling in melanocytes. C-kit stimulation recruits p300/CBP to microphthalmia. *J Biol Chem* 1998;273:17983–17986.
104. Jane-Valbuena J, Widlund HR, Perner S, et al. An oncogenic role for ETV1 in melanoma. *Cancer Res* 2010;70:2075–2084.
105. Bastiaens M, ter Huurne J, Gruis N, et al. The melanocortin-1-receptor gene is the major freckle gene. *Hum Mol Genet* 2001;10:1701–1708.
106. Healy E, Jordan SA, Budd PS, et al. Functional variation of MC1R alleles from red-haired individuals. *Hum Mol Genet* 2001;10:2397–2402.
107. Khaled M, Larribere L, Bille K, et al. Microphthalmia associated transcription factor is a target of the phosphatidylinositol-3-kinase pathway. *J Invest Dermatol* 2003;121:831–836.
108. D'Orazio JA, Nobuhisa T, Cui R, et al. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. *Nature* 2006;443:340–344.
109. Cui R, Widlund HR, Feige E, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. *Cell* 2007;128:853–864.
110. Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. *Science* 2013;339:957–959.
111. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. *Science* 2013;339:959–961.
112. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature* 2010;463:191–196.
113. International Cancer Genome Consortium, Hudson TJ, Anderson W, et al. International network of cancer genome projects. *Nature* 2010;464:993–998.
114. Bucheit AD, Davies MA. Emerging insights into resistance to BRAF inhibitors in melanoma. *Biochem Pharmacol* 2014;87:381–389.
115. Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. *J Clin Oncol* 2013;31:1767–1774.
116. Wilmott JS, Tembe V, Howle JR, et al. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. *Mol Cancer Ther* 2012;11:2704–2708.
117. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711–723.
118. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med* 2012;366:2455–2465.
119. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 2012;366:2443–2454.
120. Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. *Nat Med* 2013;19:747–752.
121. Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. *Cancer Res* 2010;70:5213–5219.
122. Dong Y, Richards JA, Gupta R, et al. PTEN functions as a melanoma tumor suppressor by promoting host immune response. *Oncogene* 2013 (ePub ahead of print).